25 citations
,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Targeted cytokine treatments may help with alopecia areata, but more research is needed.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
4 citations
,
June 2025 in “Cell Reports” Clonally expanded CD8+ T cells cause alopecia areata.
3 citations
,
May 2025 in “Carbohydrate Polymers” The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
3 citations
,
April 2022 in “F1000Research” Understanding biological mediators in skin healing can improve treatments for skin wounds.
1 citations
,
November 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
April 2025 in “BMC Immunology” Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
January 2022 in “Faculty of 1000 Research Ltd” Understanding molecular mediators can improve skin healing treatments.
December 2021 in “Figshare” New therapies like JAK inhibitors and stem cells show promise for treating vitiligo.
18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
2 citations
,
December 2024 in “eLife” JAK inhibition reduces autoimmune issues in Down syndrome.
November 2025 in “Journal of Medicinal Chemistry” Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
90 citations
,
October 2023 in “Advanced Drug Delivery Reviews” Controlling inflammation can help heal diabetic foot ulcers.
32 citations
,
August 2024 in “Journal of Investigative Dermatology” In vitro skin models are improving but still need more innovation to fully replicate human skin.
13 citations
,
April 2022 in “Journal of Mind and Medical Sciences” IBD treatment is complex and requires personalized approaches due to varying patient responses.
9 citations
,
May 2023 in “Stem Cell Research & Therapy” Stem cell treatment from umbilical cords reduces symptoms of atopic dermatitis and may help hair growth.
8 citations
,
July 2024 in “Children” Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
3 citations
,
September 2025 in “ChemMedChem” Multitarget drugs are needed to better treat complex diseases.
3 citations
,
January 2025 in “International Journal of Biological Macromolecules” A new microneedle patch effectively promotes hair regrowth with less frequent dosing.
2 citations
,
September 2025 in “International Journal of Nanomedicine” Extracellular vesicles can help treat skin issues like wounds, hair loss, aging, and inflammation.
2 citations
,
November 2019 in “International Journal of Dermatology and Venereology” Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.
January 2026 in “Journal of Investigative Dermatology” Special cells can help regrow hair in alopecia areata.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
July 2024 in “International Journal of Molecular Sciences” Hemp seed biomaterials may reduce hair loss and improve hair growth.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.